Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia

Hospital Universitari i Politècnic la Fe, Valenza, Valencia, Spain
Thrombosis Research (Impact Factor: 2.45). 07/1987; 46(5):705-714. DOI: 10.1016/0049-3848(87)90272-6


Alterations in the coagulation system are common in patients with liver disease. We have examined the importance of the species and chains of fibrinogen in 3 groups of cirrhotic patients. The study of the gelation of fibrinogen in cirrhotic patients shows that the lag time increases in 80.3% of them and that the maximum gelation rate is altered in 51% of these plasmas. Also it is observed that 80% of the plasmas from cirrhotic patients have a percentage (23.3 ± 7.7%) of unpolymerized α chain, after highly cross-linked fibrin formation. These alterations, in lag time and in the maximum gelation rate, have no significant correlation with the situation of the fibrinolytic system in these patients.The study of isolated fibrinogen from cirrhotic patients and normal subjects plasma, shows that there are no objetive alterations in the percentage of fibrinogen species, the amount of sialic acid or the ratio of polypeptide chains.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Different fibrinogen species were examined in normal plasma following urokinase treatment, in isolated high molecular weight fibrinogen treated with plasmin and in plasma samples from patients with acute myocardial infarction receiving thrombolytic therapy. In normal plasmas two main fibrinogen species (Mr = 340,000 and Mr = 320,000) and an intermediate fragment (Mr = 330,000) were observed. The 340,000 fibrinogen was the most sensitive to degradation; it gave rise to 330,000 and 320,000 species. Degradation of isolated 340,000 fibrinogen was similar to plasma fibrinogen degradation. After thrombolytic therapy in acute myocardial infarction patients, when the plasma fibrinogen decreased near to zero, the new synthesized fibrinogen was 340,000 form. 'In vivo' conversion of 340,000 to 320,000 fibrinogen, associated with the transitory 330,000 form, was observed. The coagulation study of plasma fibrinogen showed that when Mr 340,000 fibrinogen decreased (40%), the gelation rate decreased and lag time increased drastically. The high 340,000 fibrinogen content found in acute myocardial infarction patients gave rise to the hypercoagulable state.
    Clinica Chimica Acta 10/1989; 184(1):7-17. DOI:10.1016/0009-8981(89)90252-0 · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fibrinogen activity was studied in 70 patients with AMI who were treated with an intravenous infusion of SK (800,000 U/30 min or 1.5 mill U/60 min). Patients received a continuous infusion of heparin after thrombolytic therapy was completed. 800,000 U and 1.5 mill U SK recanalized infarct-related arteries at a rate of 78%. Early re-infarction occurred in 6% in each group. Upon admission to the hospital patients showed a hypercoagulable state that may be related to an elevated level of fibrinogen and HMW fibrinogen (70.5±2 vs 65±2 % in patient and normal plasmas, respectively) that changed to a transitory hypocoagulable state indicated by decreased fibrinogen levels after SK treatment. Forty-eight hours after SK, a new fibrinogen hyperfunction, related to an increase in fibrinogen level and especially HMW synthesized fibrinogen (82±1 or 81±1%, 800,000 and 1.5 mill U SK, respectively) was observed, which was neutralized by heparin therapy (1,660 U/h with continuous infusion). The elevated levels of fibrinogen (363±21 vs 240±8 mg/dl in patient and normal plasmas, respectively) and HMW fibrinogen (70±3% with both SK doses) observed seven days after SK may be related to a hypercoagulable state that is not neutralized by the heparin dose used (5,000 U/4 h bolus). Patients who showed non-recanalization were compared with those whose arteries recanalized. The former group had a higher concentration of fibrinogen (197±31 vs 147±18 mg/dl), HMW fibrinogen (78±0.5 vs 74±0.3 %, respectively), and FPA (130±3 vs 6±4 pmol/ml) and more extensive fibrin gel formation kinetics (gelation rate 3.3±1.4 vs 1.1±0.2 OD/s × 10-4, respectively) than the second group. The hypercoagulable state found in patients with acute myocardial infarction undergoing thrombolytic therapy may be related mainly to the progression of HMW fibrinogen and fibrinogen levels.
    Thrombosis Research 04/1990; 57(5-57):783-794. DOI:10.1016/0049-3848(90)90035-B · 2.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with cirrhosis suffer from a complex haemostatic disturbance, due to abnormalities in clotting and fibrinolytic system activation and in primary haemostasis. The latter is indicated by a prolongation of bleeding time, which is a reliable indicator of platelet function in vivo. To further assess the relationship between bleeding time, degree of liver failure and clotting abnormalities in patients with cirrhosis, bleeding time was investigated in a prospective study of 70 consecutive patients with cirrhosis diagnosed by liver-needle biopsy, of whom 19 belonged to Child-Pugh class A, 29 to B and 22 to C. Among patients with cirrhosis, 40% had an abnormal bleeding time (>10 min), and 42% had a platelet count <100 000/μl. Patients with severe liver failure (class C) had a lower platelet count and a more prolonged bleeding time than patients in classes A and B. Bleeding time was significantly inversely correlated to platelet count, fibrinogen, prothrombin activity and packed cell volume, and directly correlated to serum bilirubin and D-dimer. However, in class C patients, only a significant inverse correlation between bleeding time and fibrinogen was observed. These findings indicate that in cirrhosis worsening of platelet function is closely related to the degree of liver failure. The inverse correlation between bleeding time and fibrinogen indicates that a low value of this clotting parameter may account in part for platelet dysfunction.
    Journal of Hepatology 01/1994; 20(4):531-536. DOI:10.1016/S0168-8278(05)80501-X · 11.34 Impact Factor
Show more

Similar Publications